Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations

Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations

This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA health forum 2023-09, Vol.4 (9), p.e232798-e232798
Hauptverfasser: Vokinger, Kerstin N., Perényi, Gellért, Wouters, Olivier J.
Format: Artikel
Sprache:eng
Schlagworte:
Cancer therapies
Health care expenditures
Medicare
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower.
ISSN:2689-0186
2689-0186
DOI:10.1001/jamahealthforum.2023.2798